All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Pitavastatin Offers Therapeutic Potential in Cancers Arising From Chronic Inflammation

May 30th 2024

Pitavastatin, an FDA-approved statin, may inhibit pathways that contribute to IL-33 production, which has been shown to contribute to cancer development.

Dr Halperin on the FDA Approval of Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs

May 30th 2024

Daniel M. Halperin, MD, discusses the FDA approval of lutetium Lu 177 dotatate for pediatric patients with SSTR-positive GEP-NETs.

Recent Data Shed Further Light on the MDS Treatment Paradigm as the SOC Evolves

May 30th 2024

Jeremy Allred, MD, details current and emerging treatments for patients with myelodysplastic syndrome, highlighting recent key data updates.

Revisit Every OncLive On Air Episode From May 2024

May 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

AGuIX Receives FDA Fast Track Designation in Glioblastoma

May 30th 2024

AGuIX has been granted FDA fast track designation in malignant gliomas and glioblastoma.

Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC

May 30th 2024

Frontline rivoceranib plus camrelizumab continued to show a significant improvement in OS vs sorafenib in advanced unresectable hepatocellular carcinoma.

FDA Approves Liso-Cel for R/R Mantle Cell Lymphoma After 2 Lines of Therapy

May 30th 2024

The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a BTK inhibitor.

Fox Chase’s Dr. Daniel Geynisman Named Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network

May 30th 2024

Daniel M. Geynisman, MD, of Fox Chase Cancer Center, has been appointed editor-in-chief for Journal of the National Comprehensive Cancer Network.

Atezolizumab Elicits Numerical Improvement in 3-Year EFS, DFS in HER2+ Early Breast Cancer

May 30th 2024

Adding atezolizumab to neoadjuvant pertuzumab, trastuzumab, and chemotherapy produced improved EFS and DFS rates in HER2-positive early breast cancer.

PSMA Response Is Associated With MFS Improvement in Oligometastatic CSPC

May 30th 2024

PSMA response was associated with improved metastasis-free survival in oligometastatic castration-sensitive prostate cancer.

Immune Therapy Drugs Show Promise in Treating Esophageal Cancer

May 29th 2024

A medical team at AHN tested two courses of neoadjuvant immunotherapy for advanced gastroesophageal cancer — a relatively rare disease.

FDA Grants Accelerated Approval to Selpercatinib for Pediatric RET+ Metastatic Thyroid Cancer or Solid Tumors

May 29th 2024

The FDA has granted accelerated approval to selpercatinib for pediatric patients with select RET-altered metastatic thyroid cancers or solid tumors.

AFM24 Plus Atezolizumab Wins FDA Fast Track Designation for EGFR Wild-Type NSCLC

May 29th 2024

The FDA granted fast track designation AFM24 plus atezolizumab for advanced EGFR wild-type non–small cell lung cancer.

FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy for Advanced Pleural Mesothelioma

May 29th 2024

The FDA granted priority review to an sBLA seeking the approval of pembrolizumab plus chemotherapy as frontline therapy in malignant pleural mesothelioma.

Frontline Nivolumab/Chemo Approved in Europe for Unresectable or Metastatic Urothelial Cancer

May 29th 2024

The European Commission approved nivolumab plus cisplatin and gemcitabine for first-line treatment in unresectable or metastatic urothelial carcinoma.

Inavolisib Plus Palbociclib/Fulvestrant Earns FDA Priority Review for Advanced HR+/HER2–, PIK3CA+ Breast Cancer

May 29th 2024

The FDA granted priority review to inavolisib plus palbociclib/fulvestrant for HR-positive, HER2-negative, advanced breast cancer with PIK3CA mutations.

FDA Grants Priority Review to Zanidatamab for HER2+ Metastatic Biliary Tract Cancer

May 29th 2024

Zanidatamab has received priority review from the FDA for the treatment of patients with HER2-positive metastatic biliary tract cancer.

Nivolumab/Cabozantinib Combination Displays Activity in Non-Clear Cell RCC

May 29th 2024

Treatment with nivolumab plus cabozantinib yielded responses in patients with non-clear cell renal cell carcinoma.

CT041 Shows Tolerability and Early Efficacy in Refractory Metastatic Pancreatic Cancer

May 29th 2024

CT041 was safe and showcased early signals of antitumor activity in heavily pretreated patients with metastatic pancreatic cancer.

Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression

May 28th 2024

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.